Cost-effectiveness analysis of first-line serplulimab combined with chemotherapy for extensive-stage small cell lung cancer

BackgroundFor patients with extensive-stage small cell lung cancer (ES-SCLC), serplulimab plus chemotherapy is beneficial as the first-line treatment. It is uncertain whether serplulimab plus chemotherapy will be more cost-effective. The aim of this study was to evaluate from the perspective of the...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Xueyan Liang (Tekijä), Xiaoyu Chen (Tekijä), Huijuan Li (Tekijä), Yan Li (Tekijä)
Aineistotyyppi: Kirja
Julkaistu: Frontiers Media S.A., 2023-08-01T00:00:00Z.
Aiheet:
Linkit:Connect to this object online.
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Internet

Connect to this object online.

3rd Floor Main Library

Saatavuus: 3rd Floor Main Library
Hyllypaikka: A1234.567
Nide 1 Saatavissa